Research.Patient.info
HER2-positive advanced breast cancer research hub
2 indexed studies · 0 currently recruiting
- ongoing, recruitingTherapeutic confirmatory (Phase III)
EPIK-B2: A two part, Phase III, multicenter, randomized (1:1), double-blind, placebo-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with trastuzumab and pertuzumab as maintenance therapy in patients with HER2-positive advanced breast cancer with a PIK3CA mutation
This study is looking at a new treatment called alpelisib, combined with two other drugs (trastuzumab and pertuzumab), for advanced HER2-positive breast cancer with a specific gene change (PIK3CA mutation). It aims to see how safe and effective this combination is.
France - authorisedPhase I and Phase II (Integrated)- Other
PHASE IB/II STUDY TO EVALUATE SAFETY AND PRELIMINARY EFFICACY OF ZANIDATAMAB IN COMBINATION WITH TUCATINIB AND CHEMOTHERAPY (CAPECITABINE OR ERIBULIN MESYLATE) IN HER2-POSITIVE ADVANCED BREAST CANCER (The JAZMINE Study)
This study, called JAZMINE, is testing a new combination of medicines for a type of advanced breast cancer. It combines a new drug, zanidatamab, with existing treatments like tucatinib and chemotherapy (capecitabine or eribulin) to see if it's safe and effective.
Spain